Risk Factors Associated with COVID-19 Hospitalization and Mortality: A Large Claims-Based Analysis Among People with Type 2 Diabetes Mellitus in the United States.
COVID-19
Claim-based analysis
Risk factors
SARS-CoV-2
Type 2 diabetes
Journal
Diabetes therapy : research, treatment and education of diabetes and related disorders
ISSN: 1869-6953
Titre abrégé: Diabetes Ther
Pays: United States
ID NLM: 101539025
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
28
04
2021
accepted:
28
06
2021
pubmed:
19
7
2021
medline:
19
7
2021
entrez:
18
7
2021
Statut:
ppublish
Résumé
Diabetes has been identified as a high-risk comorbidity for COVID-19 hospitalization. We evaluated additional risk factors for COVID-19 hospitalization and in-hospital mortality in a nationwide US database. This retrospective study utilized the UnitedHealth Group Clinical Discovery Database (January 1, 2019-July 15, 2020) containing de-identified nationwide administrative claims, SARS-CoV-2 laboratory test results, and COVID-19 inpatient admissions data. Logistic regression was used to understand risk factors for hospitalization and in-hospital mortality among people with type 2 diabetes (T2D) and in the overall population. Robustness of associations was further confirmed by subgroup and sensitivity analyses in the T2D population. A total of 36,364 people were identified who were either SARS-CoV-2 In this nationwide US analysis, T2D was identified as an independent risk factor for COVID-19 complications. Many factors conferred similar risk of hospitalization across both populations; however, particular diabetes medications may be markers for differential risk. The insights on comorbidities and medications may inform population health initiatives, including prevention efforts for high-risk patient populations such as those with T2D.
Identifiants
pubmed: 34275115
doi: 10.1007/s13300-021-01110-1
pii: 10.1007/s13300-021-01110-1
pmc: PMC8286432
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2223-2239Informations de copyright
© 2021. The Author(s).
Références
Li H, Liu SM, Yu XH, Tang SL, Tang CK. Coronavirus disease 2019 (COVID-19): current status and future perspectives. Int J Antimicrob Agents. 2020;55(5):105951.
doi: 10.1016/j.ijantimicag.2020.105951
WHO Director-General’s opening remarks at the media briefing on COVID19. 2020. https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020 . Accessed 20 Apr 2020.
World Health Organization. Coronavirus disease (COVID-2019) situation reports-90. 2021. https://www.who.int/publications/m/item/weekly-epidemiological-update---2-february-2021 . Accessed 05 Feb 2021.
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
doi: 10.1016/S0140-6736(20)30183-5
Chen Y, Yang D, Cheng B, et al. Clinical characteristics and outcomes of patients with diabetes and COVID-19 in association with glucose-lowering medication. Diabetes Care. 2020;43(7):1399–407.
doi: 10.2337/dc20-0660
Centers for Disease Control and Prevention. Evidence used to update the list of underlying medical conditions that increase a person’s risk of severe illness from COVID-19. 2020. https://stacks.cdc.gov/view/cdc/89840 . Accessed 30 Aug 2020.
CDC COVID-19 Response Team. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019-United States, February 12-March 28, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(13):382–6.
doi: 10.15585/mmwr.mm6913e2
Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–13.
doi: 10.1016/S0140-6736(20)30211-7
Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan. China JAMA Intern Med. 2020;180(7):934–43.
doi: 10.1001/jamainternmed.2020.0994
Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020;323(18):1775–6.
pubmed: 32203977
Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020;369:m1966.
doi: 10.1136/bmj.m1966
Liu K, Fang YY, Deng Y, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J (Engl). 2020;133(9):1025–31.
doi: 10.1097/CM9.0000000000000744
Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA. 2020;323(16):1574–81.
doi: 10.1001/jama.2020.5394
Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323(20):2052–9.
doi: 10.1001/jama.2020.6775
Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62.
doi: 10.1016/S0140-6736(20)30566-3
Zhang JY, Shang T, Ahn D, et al. How to best protect people with diabetes from the impact of SARS-CoV-2: report of the international COVID-19 and diabetes summit. J Diabetes Sci Technol. 2021. https://doi.org/10.1177/1932296820978399 .
doi: 10.1177/1932296820978399
pubmed: 34328026
pmcid: 7925443
Zhu L, She ZG, Cheng X, et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab. 2020;31(6):1068-1077.e3.
doi: 10.1016/j.cmet.2020.04.021
Bode B, Garrett V, Messler J, et al. Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States. J Diabetes Sci Technol. 2020;14(4):813–21.
doi: 10.1177/1932296820924469
Seiglie J, Platt J, Cromer SJ, et al. Diabetes as a risk factor for poor early outcomes in patients hospitalized with COVID-19. Diabetes Care. 2020;43(12):2938–44.
doi: 10.2337/dc20-1506
Drucker DJ. Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications. Endocr Rev. 2020;41(3):bnaa011.
doi: 10.1210/endrev/bnaa011
Bornstein SR, Rubino F, Khunti K, et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020;8(6):546–50.
doi: 10.1016/S2213-8587(20)30152-2
Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613–9.
doi: 10.1016/0895-4356(92)90133-8
Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–9.
doi: 10.1097/01.mlr.0000182534.19832.83
Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53(12):1258–67.
doi: 10.1016/S0895-4356(00)00256-0
Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721–6.
pubmed: 23198714
Glasheen WP, Renda A, Dong Y. Diabetes Complications Severity Index (DCSI)-update and ICD-10 translation. J Diabetes Complicat. 2017;31(6):1007–13.
doi: 10.1016/j.jdiacomp.2017.02.018
Young BA, Lin E, Von Korff M, et al. Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization. Am J Manag Care. 2008;14(1):15–23.
pubmed: 18197741
pmcid: 3810070
Hastie T, Tibshirani R, Friedman JH. The elements of statistical learning: data mining, inference, and prediction. 2nd ed. New York: Pringer; 2009.
doi: 10.1007/978-0-387-84858-7
Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91–5.
doi: 10.1016/j.ijid.2020.03.017
Jordan RE, Adab P, Cheng KK. Covid-19: risk factors for severe disease and death. BMJ. 2020;368:m1198.
doi: 10.1136/bmj.m1198
Holman N, Knighton P, Kar P, et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. Lancet Diabetes Endocrinol. 2020;8(10):823–33.
doi: 10.1016/S2213-8587(20)30271-0
Centers for Disease Control and Prevention (CDC). People with certain medical conditions. 2021. https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html . Accessed 13 Jan 2021.
Singh AK, Singh R. Is metformin ahead in the race as a repurposed host-directed therapy for patients with diabetes and COVID-19? Diabetes Res Clin Pract. 2020;165:108268.
doi: 10.1016/j.diabres.2020.108268
Yu B, Li C, Sun Y, Wang DW. Insulin treatment is associated with increased mortality in patients with COVID-19 and type 2 diabetes. Cell Metab. 2021;33(1):65-77.e2.
doi: 10.1016/j.cmet.2020.11.014
Ursini F, Russo E, Pellino G, et al. Metformin and autoimmunity: a “New Deal” of an old drug. Front Immunol. 2018;9:1236.
doi: 10.3389/fimmu.2018.01236
Sharma S, Ray A, Sadasivam B. Metformin in COVID-19: a possible role beyond diabetes. Diabetes Res Clin Pract. 2020;164:108183.
doi: 10.1016/j.diabres.2020.108183
Xu J, Teng Y, Shang L, Gu X, Fan G, Chen Y, Tian R, Zhang S, Cao B. The effect of prior ACEI/ARB treatment on COVID-19 susceptibility and outcome: a systematic review and meta-analysis. Clin Infect Dis. 2021;72(11):e901–13.
doi: 10.1093/cid/ciaa1592
Baral R, Tsampasian V, Debski M, Moran B, Garg P, Clark A, Vassiliou VS. Association between renin-angiotensin-aldosterone system inhibitors and clinical outcomes in patients with COVID-19: a systematic review and meta-analysis. JAMA Netw Open. 2021;4(3):e213594.
doi: 10.1001/jamanetworkopen.2021.3594
Cugno M, Gualtierotti R, Casazza G, Tafuri F, Ghigliazza G, Torri A, et al. Mortality in PATIENTS with COVID-19 on renin angiotensin system inhibitor long-term treatment: an observational study showing that things are not always as they seem. Adv Ther. 2021;38(5):2709–16.
doi: 10.1007/s12325-021-01704-y